The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment – Blood Cancer Journal
This study shows that production of neutralizing antibodies against COVID are low in patients with myeloma, and impaired especially in patients receiving anti CD38 antibodies or belantamab.